Fondaparinux
Side effects
Options:
Show MedDRA Preferred Terms
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
Oedema
|
uncommon, 8.66% - 8.8%
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Rash
|
uncommon, 7.5% - 8.32%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anaemia
|
uncommon — 0.272% - 19.6%
|
1.2% - 1.22%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Gingival bleeding
|
common
|
|
|
|
|
|
|
|
|
x
|
x
|
Insomnia
|
0.917% - 5.41%
|
0.304%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
Postoperative wound infection
|
rare, 4.9%
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
Constipation
|
rare, 1.8% - 10.5%
|
2.1%
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Wound discharge increased
|
0.612% - 4.65%
|
0%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
Hypokalaemia
|
rare, 0% - 4.2%
|
0%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dizziness
|
rare, 0.612% - 4.17%
|
0%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Purpura
|
uncommon, 0% - 3.54%
|
0%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Urinary tract infection
|
1.82% - 4%
|
4%
|
|
|
|
|
x
|
x
|
x
|
|
|
Nausea
|
uncommon, 0.3% - 12.2%
|
1.2%
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Body temperature increased
|
uncommon, 0.3% - 15.4%
|
1.2% - 4.44%
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Hypotension
|
rare, 0.306% - 3.5%
|
0%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Confusional state
|
rare, 1.2% - 4.1%
|
0.3% - 0.304%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Urinary retention
|
2.9% - 2.96%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
Haemoglobin decreased
|
1.89% - 3.86%
|
|
|
|
|
|
|
|
x
|
|
|
Eruption
|
2.58% - 3.1%
|
|
|
|
|
|
|
x
|
|
|
|
Haematuria
|
uncommon, common
|
|
|
|
|
|
|
|
|
x
|
x
|
Haemoptysis
|
uncommon, common
|
|
|
|
|
|
|
|
|
x
|
x
|
Haematoma
|
uncommon — 1.2% - 2.85%
|
0.3% - 0.304%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Bullous eruption
|
0% - 3.1%
|
0.304%
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Dyspepsia
|
rare, 2.4% - 2.58%
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Postoperative hemorrhage
|
common, 0.6% - 2.4%
|
0.6% - 0.608%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Alanine aminotransferase increased
|
0.305% - 4.27%
|
|
|
|
|
|
|
|
x
|
|
|
Atrial fibrillation
|
1.03% - 3.02%
|
2.02%
|
|
|
|
|
|
|
x
|
|
|
Headache
|
rare, 1.43% - 4.53%
|
2.24%
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Diarrhoea
|
rare, 0.5% - 2.58%
|
2.4%
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Pain
|
1.7% - 2.55%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
Contusion
|
1.05% - 2.18%
|
|
|
|
|
|
|
|
x
|
|
|
Aspartate aminotransferase increased
|
0.174% - 2.82%
|
|
x
|
x
|
x
|
x
|
|
|
x
|
|
|
Chest pain
|
rare, 0.727% - 1.84%
|
1.49%
|
|
|
|
|
|
|
x
|
x
|
x
|
Epistaxis
|
uncommon, 1.09% - 1.31%
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
Ventricular tachycardia
|
0.281% - 1.66%
|
1.03%
|
|
|
|
|
|
|
x
|
|
|
Abdominal pain
|
rare, 1.27% - 1.44%
|
|
|
|
|
|
|
|
x
|
x
|
x
|
Vomiting
|
uncommon, 0.501% - 5.97%
|
1.2% - 1.49%
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Back pain
|
0.999% - 1.31%
|
|
|
|
|
|
|
|
x
|
|
|
Surgical site reaction
|
0.7% - 1.5%
|
2.4%
|
|
|
|
|
|
|
x
|
|
|
Haemorrhage
|
postmarketing — 0% - 5.02%
|
0% - 2.2%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Leg pain
|
rare, 0.908% - 1.35%
|
|
|
|
|
|
|
|
x
|
x
|
x
|
Prothrombin level decreased
|
0.272% - 1.31%
|
|
|
|
|
|
|
|
x
|
|
|
Anxiety
|
rare, 0.727% - 0.785%
|
|
|
|
|
|
|
|
x
|
x
|
x
|
Cough
|
rare, 0.636% - 2.09%
|
|
|
|
|
|
|
|
x
|
x
|
x
|
Surgical intervention
|
0.391% - 0.782%
|
|
|
|
|
|
|
|
x
|
|
|
Coagulopathy
|
uncommon
|
|
|
|
|
|
|
|
|
x
|
x
|
Pruritus
|
uncommon
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Oedema peripheral
|
uncommon
|
|
|
|
|
|
|
|
|
x
|
x
|
Hepatic function abnormal
|
uncommon, 0.436% - 1.27%
|
|
|
|
|
|
|
|
x
|
x
|
x
|
Hepatic enzyme increased
|
uncommon, 0.305% - 4.72%
|
|
|
|
|
|
|
|
x
|
x
|
x
|
Wound secretion
|
uncommon
|
|
|
|
|
|
|
|
|
x
|
x
|
Thrombocytosis
|
uncommon
|
|
|
|
|
|
|
|
|
x
|
x
|
Cardiac tamponade
|
0.35% - 0.543%
|
0.79% - 1.06%
|
|
|
|
|
|
|
x
|
|
|
Dyspnoea
|
rare, uncommon
|
|
|
|
|
|
|
|
|
x
|
x
|
Haemorrhage intracranial
|
0% - 0.131%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
Anaphylactic shock
|
postmarketing, rare
|
|
|
x
|
x
|
x
|
|
|
|
|
x
|
Angioedema
|
postmarketing, rare
|
|
|
x
|
x
|
x
|
|
|
|
|
x
|
Fatigue
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Flushing
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Gastritis
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Hyperbilirubinaemia
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Hypersensitivity
|
postmarketing, rare
|
|
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
Syncope
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Thrombocytopenia
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Thrombosis
|
postmarketing
|
|
x
|
x
|
x
|
x
|
|
|
|
|
|
Vertigo
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Oedema genital
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Heparin-induced thrombocytopenia
|
postmarketing
|
|
x
|
x
|
x
|
x
|
|
|
|
|
|
Hot flush
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Spinal haematoma
|
postmarketing
|
|
|
|
|
x
|
|
|
|
|
|
Somnolence
|
rare
|
|
|
|
|
|
|
|
|
x
|
x
|
Blister
|
|
|
x
|
x
|
x
|
x
|
|
|
|
|
|
Infection
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Eye haemorrhage
|
|
|
|
|
|
|
|
|
x
|
|
|
Gastrointestinal disorder
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Cardiac arrest
|
|
|
|
|
|
|
|
|
x
|
|
|
Cardiac failure
|
|
|
|
|
|
|
|
|
x
|
|
|
Immune system disorder
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Liver disorder
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
Mediastinal disorder
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Nervous system disorder
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Angiopathy
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Injection site haemorrhage
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
Retroperitoneal haemorrhage
|
0%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
Malnutrition
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Hepatobiliary disease
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Haemorrhagic stroke
|
|
|
|
|
|
|
|
|
x
|
|
|
Drug interaction
|
|
|
|
|
|
|
|
|
x
|
|
|
Infestation NOS
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Blood and lymphatic system disorders
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Local reaction
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
Acute coronary syndrome
|
|
|
|
|
|
|
|
|
x
|
|
|
Catheter thrombosis
|
|
|
|
|
|
|
|
|
x
|
|
|
Cerebral haemorrhage
|
|
|
|
|
|
|
x
|
x
|
|
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 26 |
Source: | FDA Structured Product Label |
---|
Side effects: | 29 |
Source: | FDA Structured Product Label |
---|
Side effects: | 29 |
Source: | FDA Structured Product Label |
---|
Side effects: | 30 |
Source: | FDA Structured Product Label |
---|
Side effects: | 32 |
Source: | FDA |
---|
Side effects: | 32 |
Source: | FDA |
---|
Side effects: | 56 |
Source: | Health Canada |
---|
Side effects: | 58 |
Source: | EMA |
---|
Side effects: | 60 |
Source: | EMA |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|